Adaptin Bio (APTN) Other Non-Current Liabilities (2025 - 2026)
Adaptin Bio's (APTN) quarterly Other Non-Current Liabilities came in at $551269.0 in Q2 2026, little changed year-over-year from $551269.0 in Q2 2025, and little changed quarter-over-quarter from $551269.0 in Q1 2026.
Powered by 
Analysis
Adaptin Bio (APTN) Other Non-Current Liabilities (2025 - 2026) Analysis & Trends
Adaptin Bio has disclosed Other Non-Current Liabilities across 2 years of filings, most recently posting $551269.0 for Q2 2026.
- In Q2 2026, Other Non-Current Liabilities changed 0.0% year-over-year to $551269.0; the TTM figure through Jun 2026 stood at $551269.0 (changed 0.0% YoY), while the FY2025 annual figure was $551269.0, changed N/A from the prior year.
- Other Non-Current Liabilities came in at $551269.0 for Q2 2026 at Adaptin Bio, roughly flat from $551269.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $551269.0 in Q1 2025 to a low of $551269.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn |
| 10 | Adaptin Bio | 56.76 Mn | 56.09 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 551,269.00 |
| Mar 31, 2026 | 551,269.00 |
| Dec 31, 2025 | 551,269.00 |
| Sep 30, 2025 | 551,269.00 |
| Jun 30, 2025 | 551,269.00 |
| Mar 31, 2025 | 551,269.00 |